80 results about "Nucleosome" patented technology

A non-invasive screening or diagnostic method for determining the likelihood of a fetus with a genetic abnormality or a potential pregnancy complication, which utilizes a liquid blood sample from a pregnant woman. Antibodies specific to a section of histone 3.1 which is exposed to a far greater extent in chromatin of fetal origin than in chromatin of maternal origin are used to sequester and isolate such fetal nucleosomes including the associated fetal DNA. Following isolation/enrichment of such fetal DNA, genetic analysis is carried out using known molecular diagnostics.

The present disclosure provides a method for enriching for multiple genomic regions using a first bait set that selectively hybridizes to a first set of genomic regions of a nucleic acid sample and a second bait set that selectively hybridizes to a second set of genomic regions of the nucleic acid sample. These bait set panels can selectively enrich for one or more nucleosome-associated regions of a genome, said nucleosome-associated regions comprising genomic regions having one or more genomic base positions with differential nucleosomal occupancy, wherein the differential nucleosomal occupancy is characteristic of a cell or tissue type of origin or disease state.

This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

The invention encompasses methods for improving the level and/or sustainability of expression for a target nucleic acid in a eukaryotic cell comprising: (a) modifying the target nucleic acid to introduce or to comprise signals that limit or constrain the positions of nucleosome cores, and (b) introducing the modified target nucleic acid into the eukaryotic cell, wherein the modified target nucleic acid has improved levels and/or sustainability of expression compared to original unmodified nucleic acid.

The invention discloses a tumor screening kit based on high-throughput sequencing technology for free DNA in peripheral blood plasma and a system and method of the tumor screening kit, and aims to provide a kit for early screening of single or multiple tumors with high sensitivity, non-mutation sites and specific gene dependence by using the peripheral blood. The kit comprises a plasma free DNA extraction reagent, a library construction reagent, a sequencing reagent, a sequencing chip and a biological information analysis method. The location information and differences of nucleosome footprints can be obtained in the whole genome range of the free DNA through the high-throughput sequencing of the free DNA in the peripheral blood plasma of healthy people and tumor patients and through bioinformatics analysis of the sequencing data, and then the clustering analysis of the tumor patients and the healthy control population is realized according to the differences of the nuclosome footprints, so as to distinguish tumor patients and the healthy control population. The purpose of the above screening is to obtain information on intermediate results. The invention belongs to the field of biotechnology.

The invention provides preparation of a circulating tumor free DNA (deoxyribonucleic acid) standard product for a simulating plasma matrix. The preparation comprises the following steps of A, purchasing a natural cell line carrying gene mutation, or editing the gene to obtain a cell line carrying the gene mutation; B, cracking a wild cell line and a gene mutation cell line, and obtaining fragmented DNA by a nucleosome enzyme digestion or ultrasonic intercepting method; mixing the fragmented DNA of the wild cell line and one or multiple fragmented DNA of the gene mutation cell line according toa ratio, so that the mixture has the required gene mutation points and mutation frequency; D, preparing simulating plasma; E, feeding the mixture in step D into the simulating plasma, fully and uniformly mixing, and verifying the property. The preparation has the advantages that a standard product of a ctDNA sample approximate to a natural sample of the human body is provided, and a standard reference substance is provided for a circulating tumor free DNA detection platform, development of detection reagents, and evaluation on laboratory detection ability.

This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)—RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

The invention discloses a cluster analysis method based on a peripheral blood plasma free DNA nucleosome footprint difference, and an application thereof. The method comprises the steps of (1), acquiring peripheral blood plasma free DNA high-flux sequencing data; (2), constructing a standard nucleosome positioning area database; (3), performing comparative analysis on each sample sequencing data and the standard nucleosome positioning area database; (4), screening coverage data of the nucleosome footprint difference and performing standardizing; and (5), performing cluster analysis on the standardized data by means of a hierarchical clustering method according to correlation between the samples. The method according to the invention has advantages of effectively preventing dependence of anexisting method to tissues or cells, comprehensively improving depth and accuracy in high-flux sequencing data analysis, realizing noninvasive radiotherapy and chemotherapy sensitivity prediction toa tumor patient, and realizing high comprehensiveness, high accuracy and high coverage. The method belongs to the field of biotechnology.

The invention provides a polypeptide and an application thereof to preparation of medicament for treatment and/or prevention of tumor. An amino acid sequence of the polypeptide is shown in a sequence table SEQ ID No.1, or shown in the sequence table SEQ ID No.1 amino acid sequence with two or more amino acids substituted by unnatural amino acids with connectable side chains, and a derivative comprises a chimeric peptide formed by connection of the polypeptide and a cell-penetrating peptide, a fusogenic peptide formed by the polypeptide and a virus, a methylated polypeptide, a glycosylated polypeptide, and a pegylated polypeptide. The polypeptide or the polypeptide derivative can targetedly increase number of PML nucleosomes, and can be applied to preparation of medicament for treatment and/or prevention of tumor.

The invention discloses a cancer detection model, a construction method thereof and a kit, and relates to the technical field of cancer detection. The method comprises the following steps: excavating nucleosome distribution characteristics, terminal sequence characteristics and fragment size distribution characteristics which can be applied to cancer detection through whole genome sequencing of plasma free DNA; constructing a classification model of the three indexes to obtain a prediction score of each index for a sample, and then using a logic regression model to integrate the scores and add copy number variation feature information to obtain a final classification prediction model. According to the cancer detection model, the efficiency and accuracy of cancer detection are remarkably improved, the amount of data needed for analysis is small, the detection cost is low, different cancers can be detected, and the cancer detection model is suitable for analyzing and predicting tumors in all periods. In addition, the kit provided by the invention can complete detection of indexes required by a detection model, so the kit can be innovatively applied to the field of cancers in ctDNA detection.

The invention relates to a new method for high-efficiently capturing a chromatin nucleosome vacancy district at a whole-cell level. The new method can locate the chromatin nucleosome vacancy district more accurately and sensitively in the range of a complete genome. The method for capturing the chromatin nucleosome vacancy district at a high-throughput complete genome level can be used to search the chromatin nucleosome vacancy district of the transcriptional regulation of eukaryotic cells, and is an effective means for functional genomics research.

The invention relates to the field of biotechnology and biomedicine, and relates to a nano-antibody aiming at H3K64Ac/H3K64 fragments and application thereof. Specifically, a VHH chain of the nano-antibody of the anti-histone 3 64 lysine acetylation (H3K64Ac) fragment has an amino acid sequence shown in SEQ ID NO:33 or SEQ ID NO:34 or SEQ ID NO:35 or SEQ ID NO:36. A VHH chain of the nano-antibody of the anti-histone 3 64 lysine non-modified (H3K64) fragment has an amino acid sequence shown in SEQ ID NO:37 or SEQ ID NO:58. The nano-antibody is efficiently expressed through microorganisms. The molecular weight of the nano-antibody does not reach 1/10 that of a conventional antibody, and therefore research on the nucleosome core region H3K64 acetylation site biological functions can be achieved.

The present invention relates to a method for producing a nucleosome preparation that is characterised by being suitable for use in immunofluorescence assays of specific antibodies directed against the nucleosomes in human samples and thus for a more specific diagnosis of disseminated lupus erythematosus (LED) compared with the state of the art.

The invention provides a noninvasive molecular subtyping kit and method for a breast cancer and aims to provide a kit which is simple to use and high in detection accuracy and a noninvasive molecularsubtyping method for a breast cancer, which makes samples easy to obtain, is simple in sampling process, good in clinical experience, capable of achieving processized operation and very suitable for clinical application and non-disease diagnosis purposes. The technical scheme of the invention is that the noninvasive molecular subtyping kit for the breast cancer comprises a plasma free DNA extraction reagent, a library construction reagent, a sequencing reagent and a sequencing chip. The method is based on high-throughput sequencing data of plasma free DNA, nucleosome footprint difference information of a promoter region in the whole genome range in the plasma free DNA is obtained by means of bioinformatic analysis, and thus noninvasive molecular subtyping of four categories of a lumen A type, a lumen B type, an HER2 enrichment type and basal cell type of a breast cancer patient is achieved according to the difference of footprint information. The invention belongs to the technical field of biology.

The invention relates to a method for detecting and measuring the presence of mono-nucleosomes and oligo-nucleosomes and the use of such measurements for the detection and diagnosis of disease.

The invention relates to an immunoblotting kit for detecting autoimmune nephrosis and a preparation method thereof, which belong to the field of biomedicine. The immunoblotting kit comprises a reaction membrane strip, an enzyme conjugate, a chromogenic substrate, a washing solution, a sample diluent and a stopping solution; the reaction membrane strip is composed of a carrier and a cellulose nitrate membrane or a nylon membrane which are fixed on the carrier, the cellulose nitrate membrane or the nylon membrane contains parallel detection lines specifically combined and coated by 4-8 kinds of natural or recombinant antigens in C1q, MPO, PR3, GBM, Nucleosome, dsDNA, PLA2R and YHSD7A, a strip of determination indication strip with high concentration being 30-50 [mu]L/mL, a strip of the determination indication strip with medium concentration being 15-25 [mu]L/mL, and a strip of the determination indication strip with low concentration being 1-10 [mu]L/mL. The kit can overcome the disadvantages of detection sensitivity and specificity of a single autoantibody as well as tedious operation for individually detecting several kinds of disease-associated autoantibodies, and can greatly increase the detection efficiency and result determination accuracy.

The invention relates to the use of a cell-free nucleosome as a biomarker in a sputum sample for the diagnosis or detection of cancer, adenoma, autoimmune disease or inflammatory disease. The invention also relates to methods of detecting said cell free nucleosomes in sputum samples, in particular in methods of diagnosis.

The invention relates to an MNase digestion optimization method applied to nucleosome loci in tissue samples. The MNase digestion optimization method includes chromatin preparation, DNA preparation, MNase digestion, DNA fragment recycle, high-throughput sequencing and frequency detection. The MNase digestion optimization method has the advantages that pre-collection methods for tissue cell nucleuses are improved, enzyme digestion reaction conditions are optimized, and enzyme digestion efficiency and recycle rate are increased; correct chromatin fragments can be acquired effectively, binding loci of regulation elements on whole genomes can be positioned and transcribed accurately, and research progresses of clinical samples are improved.

The invention relates to an improved apoptotic DNA ladder extraction kit, which comprises a cell lysis buffer used for extracting an apoptotic nucleosome of an apoptotic cell within 10 seconds, an extraction reagent enzyme A solution and an extraction reagent enzyme B solution both used for removing an RNA enzyme and nucleosome protein mixed in the apoptotic nucleosome, an ammonium acetate solution formed by an aqueous solution in which 1 mL aqueous solution contains 790 mg ammonium acetate, and a DNA ladder solution formed by a TE buffer solution of 1.667 mL and an aqueous solution in which 0.333 mL aqueous solution contains 4.4 g EDTA, 250 mg bromophenol blue and 250 mg Xylene Cyanol FF. The improved apoptotic DNA ladder extraction kit used for detecting ligand has the characteristics of quickness, high sensitivity (cells with the apoptosis rate more than 10% can be detected), capability of qualitative detection, and strong specificity.